Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Minerva Cardiology and Angiology 2021 October;69(5) > Minerva Cardiology and Angiology 2021 October;69(5):525-32



Opzioni di pubblicazione
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Cardiology and Angiology 2021 October;69(5):525-32

DOI: 10.23736/S2724-5683.20.05413-4


lingua: Inglese

Targeting “diabetic” coronary artery disease merging the properties of sirolimus coated balloon with sirolimus eluting stent

Luca TESTA 1 , Matteo CASENGHI 1, Antonio POPOLO RUBBIO 1, Sameer DANI 2, Devang DESAI 3, Rashmit PANDYA 2, Pritesh PAREKH 4, Nirav BHALANI 5, Arvind SHARMA 5, Chirag SETH 5, Francesco BEDOGNI 1

1 Department of Cardiology, IRCCS San Donato Polyclinic, Milan, Italy; 2 Life Care Institute of Medical Sciences and Research, Apollo Hospitals, Ahmedabad, India; 3 Mahavir Hospitals, Surat, India; 4 Care Hospitals, Surat, India; 5 Rhythm Heart Institute, Baroda, India

BACKGROUND: Patients with diabetes mellitus (DM) represents a challenging subset of population as they experience worse outcomes after percutaneous coronary intervention than patients without diabetes. We evaluated the 2-year efficacy and safety profile of the Abluminus DES+ in patients with diabetes within the population enrolled in the large multicenter en-ABL e-registry.
METHODS: Multicenter, prospective, all-comers registry performed in 31 centers in India. We analyze patients according to the diagnosis of DM and insulin dependency (ID or Non-ID): non-DM (1641 patients), NIDDM (721 patients), IDDM (138 patients). The primary endpoint was a composite of device-oriented major adverse cardiac events (MACE): cardiac death, target vessel-related myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)/ target vessel revascularization (TVR) at 2-year. Stent thrombosis (ST) at any time point was also recorded.
RESULTS: The MACE rate at 2-year follow-up was 3.0% in the overall population with DM patients showing a higher rate of primary endpoint compared to non-DM (4.4% vs. 2.4%, P=0.025). Rate of cardiac death was actually low and consistent between the 2 groups (1.7% vs. 0.9%, P=0.100). At 2-year follow-up, the rate of ST was 0.9% in DM patients versus 0.5% in non-DM, P=0.213.
CONCLUSIONS: At 2-year follow-up, the Abluminus DES+ technology that merges the features of a sirolimus coated balloon with those of a bioresorbable polymer drug eluting stent appears to be safe and effective. This safety/efficacy profile was consistent in patients with or without DM.

KEY WORDS: Diabetes mellitus; Drug-eluting stent; Stents

inizio pagina